Biolyst › AVIRAtea Pharmaceuticals, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 19, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 14.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 29 concluded trials, 86% reached completion rather than being terminated or withdrawn.
Track AVIR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open AVIR in the tracker
Recent history
Date Event Type Phase
September 15, 2026
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV Trial Milestone
Phase 3
August 15, 2026
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone Trial Milestone
Phase 1
August 12, 2026
Quarterly results filed (8-K) Earnings
—
May 12, 2026
Quarterly results filed (8-K) Earnings
—
April 30, 2026
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function Trial Milestone
Phase 1
March 5, 2026
Quarterly results filed (8-K) Earnings
—
February 17, 2026
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) Trial Milestone
Phase 1
January 8, 2026
Quarterly results filed (8-K) Earnings
—
November 12, 2025
Quarterly results filed (8-K) Earnings
—
August 7, 2025
Quarterly results filed (8-K) Earnings
—
July 2, 2025
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin Trial Milestone
Phase 1
June 28, 2025
Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir Trial Milestone
Phase 1
May 12, 2025
Quarterly results filed (8-K) Earnings
—
April 17, 2025
Quarterly results filed (8-K) Earnings
—
December 9, 2024
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Trial Milestone
Phase 2
August 25, 2024
Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir Trial Milestone
Phase 1
June 15, 2024
Study of AT-527 in Subjects With Normal and Impaired Renal Function Trial Milestone
Phase 1
May 30, 2024
Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir Trial Milestone
Phase 1
April 25, 2024
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 Trial Milestone
Phase 3
April 23, 2024
Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function Trial Milestone
Phase 1
May 31, 2023
Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects Trial Milestone
Phase 1
May 19, 2023
The Study of Bemnifosbuvir in Healthy Japanese Subjects Trial Milestone
Phase 1
March 16, 2023
Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model Trial Milestone
Phase 1
March 15, 2023
Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir Trial Milestone
Phase 1
January 19, 2023
Study of AT-752 in Patients With Dengue Infection Trial Milestone
Phase 2
August 23, 2022
Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal Trial Milestone
Phase 1
January 10, 2022
Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting Trial Milestone
Phase 2
December 23, 2021
Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) Trial Milestone
Phase 1
December 12, 2021
Drug-drug Interaction Study of Digoxin and AT-527 (R07496998) Trial Milestone
Phase 1
November 14, 2021
Study of AT-752 in Healthy Subjects Trial Milestone
Phase 1
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.